A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Trial Profile

A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2017

At a glance

  • Drugs HI-con1 (Primary) ; Ranibizumab
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms EMERGE
  • Sponsors Iconic Therapeutics
  • Most Recent Events

    • 09 Feb 2017 According to an Iconic Therapeutics, results from this trial will be presented at the Angiogenesis, Exudation, and Degeneration meeting 2017.
    • 11 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 11 Apr 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top